Matrix metalloproteinases (MMPs), and, in particular, gelatinases (MMP-2 and MMP-9), have been implicated in vascular cell proliferation and/or migration, contributing to intimal thickening, an essential stage in the development of atherosclerosis and restenosis following balloon angioplasty. Endothelin, a strong chemoatractant and mitogen, has been shown to promote smooth muscle cell proliferation and migration by activating MMPs via endothelin-A (ETA) receptors. The positioning of a soft silicon collar around the left carotid artery in rabbits results in intimal thickening. In this study, we investigate the possible role of gelatinases and the effect of a nonselective ETA/ETB receptor antagonist, TAK-044 (5 mg/kg body weight/day, subcutaneously [sc]), on these enzymes. Our results demonstrated that both MMP-2 and MMP-9 activities increased in response to collaring in placebo group, while treatment with TAK-044 significantly suppressed both gelatinase activities and proMMP-2 levels, and inhibited intimal thickening in collared arteries. These results suggest that either enhanced MMP expression or endothelin receptor antagonism may be involved in the formation of intimal thickening in this model.
Lessner SM, Martinson DE, Galis ZSCompensatory vascular remodeling during atherosclerotic lesion growth depends on matrix metalloproteinase-9 activity. Arterioscler Thromb Vasc Biol. 2004;24(11):2123-2129.
2.
Garcia-Touchard A., Henry TD, Sangiorgi G., et al. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb Vasc Biol. 2005;25(6):1119-1127.
3.
Newby ACDual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005;85(1):1-31.
4.
Dollery CM, Mc Ewan JR, Henney AMMatrix metalloproteinases and cardiovascular disease. Circ Res.1995;77(5):863-868.
5.
Zempo N., Koyama N., Kenagy RD, Lea HJ, Clowes AWRegulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor . Arterioscler Thromb Vasc Biol. 1996;16(1):28-33.
6.
Bendeck MP, Zempo N., Clowes AW, Galardy RE, Reidy MASmooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994 ;75(3):539-545.
7.
Southgate KM , Fisher M., Banning AP, et al. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. 1996;79(6):1177-1187.
8.
Kenagy RD, Hart CE, Stetler-Stevenson WG, Clowes AWPrimate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation. 1997;96(10):3555-3560.
9.
Aoyagi M., Yamamato M., Azuma H., et al. Smooth muscle cell proliferation, elastin formation and tropoelastin transcripts during the development of intimal thickening in rabbit carotid arteries after endothelial denudation. Histochem Cell Biol . 1997;107(1):11-17.
10.
Godin D., Ivan E., Johnson C., Magid R., Galis ZSRemodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation . 2000;102(23):2861-2866.
11.
Lijnen HR, Soloway P., Collen D.Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Circ Res. 1999;85(12):1186-1191.
12.
Bayes-Genis , Kantor B, Keelan PC, et al. Restenosis and hyperplasia. Animal models. Curr Interv Cardiol Rep.2000;2(4):303-308.
13.
De Meyer GR , Bult H.Mechanisms of neointima formation-lessons from experimental models. Vasc Med. 1997;2(3):179-189.
14.
Booth RF, Martin JF, Honey AC, Hassal G., Beesley JE, Moncada S.Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis. 1989;76(2-3):257-268.
15.
Dashwood MR , Jagroop IA, Gorog DA, Bagger JPA potential role for endothelin-1 in peripheral vascular disease. J Cardiovasc Pharmacol.2000;36(5 suppl):93-94.
16.
Kirchengast M., Munter K.Endothelin and restenosis. Cardiovasc Res.1998;39(3):550-555.
17.
Lerman A., Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr.Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis . N Engl J Med. 1991;325(14):997-1001.
18.
Mitani H., Takimoto M., Bandoh T., Kimura M.Increases of vascular endothelin-converting enzyme activity and endothelin-1 level on atherosclerotic lesions in hyperlipidemic rabbits. Eur J Pharmacol. 2000;387(3):313-319.
19.
Kitamura A. , Kagami S., Urushihara M., et al. Endothelin-1 is a potent stimulator of alpha1 beta1 integrin-mediated collagen matrix remodeling by rat mesangial cells. Biochem Biophys Res Commun. 2002;299(4):555-561.
20.
Rosanò L., Varmi M., Salani D., et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 2001;61(22): 8340-8346.
21.
Rosano L., Salani D., Di Castro V., Spinella F., Natali PG, Bagnato A.Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci. 2002;103(suppl 48): 306-309.
22.
Reel B., Ozkal S., Islekel H., et al. The role of endothelin receptor antagonism in collar-induced intimal thickening and vascular reactivity changes in rabbits. J Pharm Pharmacol. 2005;57(12):1599-1608.
23.
Tsujino M., Hirata Y., Eguchi S., Watanabe T., Chatani F., Marumo F.Nonselective ETA/ETB receptor antagonist blocks proliferation of rat vascular smooth muscle cells after balloon angioplasty. Life Sci.1995;56(25):PL449-PL454.
24.
Snoek-van Beurden PA, Von den Hoff JWZymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques . 2005;38(1):73-83.
25.
Hofmann UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GNExpression and activation of matrix metalloproteinase-2 (MMP2) and its co-localization with membrane-type I matrix metalloproteinase (MTI-MMP) correlate with melanoma progression. J Pathol. 2000;191(3):245-256.
26.
Sarioğlu S., Ozer E., Kirimca F., Sis B., Pabuçcuoğlu U.Matrix metalloproteinase-2 expression in laryngeal pre-neoplastic and neoplastic lesions. Pathol Res Pract. 2001;197(7):483-486.
27.
Wiechelman KJ , Braun RD, Fitzpatrick JDInvestigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem. 1988;175(1):231-237.
28.
Heussen C., Dowdle EBElectrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem. 1980;102(1):196-202.
29.
Galis ZS, Khatri JJMatrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad and the ugly. Circ Res. 2002;90(3):251-262.
30.
Jones CB, Sane DC, Herrington DMMatrix metalloproteinases. A review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003;59(4):812-823.
31.
Feldman LJ, Mazighi M., Scheuble A., et al. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit. Circulation. 2001;103(25): 3117-3122.
32.
Davies MJAortic aneurysm formation: lessons from human studies and experimental models . Circulation. 1998;98(3):193-195.
33.
Ustunes L., Yasa M., Kerry Z., et al. Effect of verapamil on intimal thickening and vascular reactivity in the collared carotid artery of the rabbit. Br J Pharmacol . 1996;118(7):1681-1688.
34.
Nagase H., Visse R., Murphy G.Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-573.
35.
Visse R., Nagase H.Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003 ;92(8):827-839.
36.
Galis ZS, Kranzhöfer R., Fenton JW 2nd, Libby P.Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol.1997;17(3):483-489.
37.
Lijnen HR, Silence J., Lemmens G., Frederix L., Collen D.Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb Haemost. 1998;79(6):1171-1176.
38.
Wang M., Lakatta EGAltered regulation of matrix metalloproteinase-2 in aortic remodeling during aging. Hypertension. 2002;39(4):865-873.
39.
Song W., Ergul A.Type-2 diabetes-induced changes in vascular extracellular matrix gene expression: relation to vessel size. Cardiovasc Diabetol. 2006;5:1-7.
40.
Ammarguellat FZ, Gannon PO, Amiri F., Schiffrin ELFibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension. 2002;39(2 pt 2): 679-684.
41.
Felx M., Guyot MC, Isler M., et al. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-kappa B in human osteosarcoma. Clin Sci. (Lond). 2006;110(6):645-654.
42.
Ergul A., Portik-Dobos V., Giulumian AD, Molero MM, Fuchs LCStress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation. Am J Physiol Heart Circ Physiol.2003;285(5): H2225-H2232.
43.
Podesser BK , Siwik DA, Eberli FR, et al. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol. 2001;280(3):984-991.
44.
Harris AK, Hutchinson JR, Sachidanandam K., et al. Type 2 diabetes causes remodeling of cerebrovasculature via differential regulation of matrix metalloproteinases and collagen synthesis: role of endothelin-1. Diabetes. 2005;54(9):2638-2644.
45.
Masuda Y., Sugo T., Kikuchi T., et al. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelin A and endothelin B receptors. J Pharmacol Exp Ther.1996;279(2):675-685.
46.
Olson MW, Bernardo MM, Pietila M., et al. Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1J Biol Chem.2000;275(4): 2661-2668.
47.
Bellosta S. , Baetta R., Canavesi M., et al. Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells. Pharmacol Res. 2007;56(2):160-167.
48.
Winberg JO, Berg E., Kolset SO, Uhlin-Hansen L.Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem.2003; 270(19):3996-4007.
